Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer.

PubWeight™: 0.89‹?›

🔗 View Article (PMID 10589749)

Published in Clin Cancer Res on November 01, 1999

Authors

A Chaudhry1, J A Carrasquillo, I L Avis, N Shuke, J C Reynolds, R Bartholomew, S M Larson, F Cuttitta, B E Johnson, J L Mulshine

Author Affiliations

1: Intervention Section, Department of Cell and Cancer Biology, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892-1906, USA.

Articles by these authors

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34

A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00

Radiometric detection of the metabolic activity of Mycobacterium tuberculosis. J Nucl Med (1975) 5.30

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (1985) 4.47

Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods (1984) 4.15

Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol (2000) 4.10

NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl (1996) 3.24

Automated detection of Haemophilus influenzae. Appl Microbiol (1973) 3.16

A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst (2000) 2.95

Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer (1997) 2.81

Brownian dynamics of cytochrome c and cytochrome c peroxidase association. Science (1988) 2.78

Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol (1995) 2.78

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol (2001) 2.73

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64

Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature (1987) 2.59

Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res (1998) 2.55

Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst (1997) 2.52

Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med (1996) 2.51

Antigens associated with Plasmodium falciparum infections in man. Lancet (1969) 2.45

A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res (1998) 2.43

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38

Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs. Arch Intern Med (1993) 2.36

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer (2008) 2.21

Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A (1998) 2.20

Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst (1991) 2.19

Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med (1985) 2.12

Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res (1992) 2.09

Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg (1996) 2.03

Imaging transgene expression with radionuclide imaging technologies. Neoplasia (2000) 2.03

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00

Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood (1995) 1.99

Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol (2002) 1.96

IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines. Cancer Res (1993) 1.96

Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95

Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res (1997) 1.94

Tanning with ultraviolet A sunbeds. BMJ (1990) 1.93

Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med (1999) 1.92

[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab (1999) 1.90

Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev (1997) 1.88

NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J Sci Am (1999) 1.86

Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab (1995) 1.84

Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol (1992) 1.84

Tanning, protection against sunburn and vitamin D formation with a UV-A 'sun-bed'. Br J Dermatol (1982) 1.79

Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene (1991) 1.79

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol (1999) 1.77

Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst (1995) 1.76

Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med (2000) 1.74

Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys (2004) 1.74

Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst (1993) 1.73

Extent of Barrett's metaplasia: a prospective study of the serial change in area of Barrett's measured by quantitative endoscopic imaging. Gastrointest Endosc (1997) 1.72

SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. J Med Genet (2005) 1.71

Quantitative imaging of iodine-124 with PET. J Nucl Med (1996) 1.69

Characteristics of cell lines established from human colorectal carcinoma. Cancer Res (1987) 1.69

Neural tube defects in hurricane aftermath. Lancet (1991) 1.69

Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab (1999) 1.68

Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer. J Clin Invest (1971) 1.68

Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67

Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med (1993) 1.66

Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med (1993) 1.65

Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A (1990) 1.63

Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res (1992) 1.61

Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin Cancer Res (2000) 1.61

Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. J Thorac Cardiovasc Surg (2001) 1.60

Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab (2006) 1.60

Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid (2000) 1.59

Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab (2000) 1.59

MDR1 gene expression in lung cancer. J Natl Cancer Inst (1989) 1.57

Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol (1998) 1.56

Estimation of body fatness by air displacement plethysmography in African American and white children. Pediatr Res (2001) 1.55

The curve of Spee revisited. Am J Orthod Dentofacial Orthop (1996) 1.54

Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. Br J Dermatol (1993) 1.54

Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res (1987) 1.53

Visualization of the thymus with therapeutic doses of radioiodine in patients with thyroid cancer. Eur J Nucl Med (1993) 1.52

Hallux valgus assessment: report of research committee of American Orthopaedic Foot and Ankle Society. Foot Ankle (1984) 1.52

Phase and amplitude binning for 4D-CT imaging. Phys Med Biol (2007) 1.52

Effect of metabolism on retention of indium-111-labeled monoclonal antibody in liver and blood. J Nucl Med (1994) 1.51

Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem (2000) 1.50

Characteristics of cell lines established from human gastric carcinoma. Cancer Res (1990) 1.49

Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning. J Nucl Med (1966) 1.49

A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol (2001) 1.49

Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung. Cancer (1999) 1.49

Soft tissue profile: a survey of African-American preference. Am J Orthod Dentofacial Orthop (1995) 1.49

FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med (2001) 1.49

Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys (2002) 1.48

Technetium-99m-tetrofosmin would be a substrate for multidrug resistance-associated protein (MRP): comparison between a leukemia cell line with high MRP gene expression and its parental cell line. Cancer Biother Radiopharm (2001) 1.48

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene (2000) 1.47

Scientific basis for cancer prevention. Intermediate cancer markers. Cancer (1993) 1.47

Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol (1999) 1.47

In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst (1989) 1.46

6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension (2001) 1.45

myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest (1987) 1.43

Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African American and white children. J Pediatr (2001) 1.43

In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43